Central Bank Trust Co Exits Position in PharMerica Corporation (PMC)

PharMerica Corporation (PMC) : Central Bank Trust Co has sold out all of its stake in PharMerica Corporation during the most recent quarter, according to the disclosure filed by the company on Oct 7, 2016 with the SEC. The investment management company has sold out 380 shares of PharMerica Corporation which is valued at $10,625.

Other Hedge Funds, Including , Simplex Trading sold out all of its stake in PMC during the most recent quarter. The investment firm sold 77 shares of PMC which is valued $2,153.Bnp Paribas Arbitrage Sa reduced its stake in PMC by selling 5,395 shares or 52.36% in the most recent quarter. The Hedge Fund company now holds 4,908 shares of PMC which is valued at $136,491.Eqis Capital Management boosted its stake in PMC in the latest quarter, The investment management firm added 822 additional shares and now holds a total of 14,343 shares of PharMerica Corporation which is valued at $398,879. PharMerica Corporation makes up approx 0.03% of Eqis Capital Management’s portfolio.

PharMerica Corporation closed down -0.17 points or -0.60% at $27.96 with 1,96,340 shares getting traded on Friday. Post opening the session at $28.21, the shares hit an intraday low of $27.61 and an intraday high of $28.255 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, PharMerica Corporation reported $0.47 EPS for the quarter, based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus estimate of $0.47. The company had revenue of $519.60 million for the quarter, compared to analysts expectations of $508.31 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.

PharMerica Corporation is an institutional pharmacy services company. The Company has three operating segments: institutional pharmacy specialty infusion services and specialty oncology pharmacy. The Company’s core business institutional pharmacy segment provides pharmacy products and services to residents and patients in skilled nursing facilities nursing centers assisted living facilities hospitals and other long-term alternative care settings. The Company’s specialty infusion services segment provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities hospice and outside of hospital or nursing home settings. The Company’s specialty oncology pharmacy segment provides dispensing of oncology drugs care management and other related services to patients oncology practices and hospitals.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *